Science

Shamir Geller: Our experience with JAK inhibitors in patients with cutaneous lymphoma

Shamir Geller/mskcc.org

Apr 20, 2025, 16:21

Shamir Geller: Our experience with JAK inhibitors in patients with cutaneous lymphoma

Shamir Geller, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, shared a post on LinkedIn about a paper he co-authored published in the Journal of Dermatology:

“Just accepted for publication – our experience with JAK inhibitors in patients with cutaneous lymphoma from our Memorial Sloan Kettering Cancer Center cutaneous lymphoma clinic.

More on this topic to come…”

“Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T-Cell Lymphoma: A Real-World Single-Center Experience”

Authors: Viviane Liao, Leore Lavin, Michael Ong, Melissa Pulitzer, Alison Moskowitz, Patricia Myskowski, Shamir Geller.

Shamir Geller: Our experience with JAK inhibitors in patients with cutaneous lymphoma

Alison Moskowitz cancer Cutaneous Lymphoma Journal of Dermatology Leore Lavin Melissa Pulitzer Memorial Sloan Kettering Cancer Center Michael Ong OncoDaily Oncology Patricia Myskowski Shamir Geller Viviane Liao

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth